The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research
Fifteen (15) RAMP UP grants were awarded in total, with participants currently progressing through various stages of the consignment agreement process. Upon completion, participants will use the OhmX platform to analyze structural variants (SVs) for various applications, including rare disease, cancer, and cell and gene therapy. Some specific applications include the analysis of repeat expansions, orthogonal confirmation of long-read sequencing calls, determining detection sensitivity for rare SVs, and enhanced cytogenetic profiling.
'I look forward to establishing electronic genome mapping as a core service for the Boston Children's Hospital research community. The technology seems promising for high-resolution analysis of structural variants' said Dr. Catherine Brownstein, a RAMP UP recipient at Boston Children's Hospital and Director of the Genomics Core.
The institutions participating in the program include:
Ann & Robert H. Lurie Children's Hospital of Chicago (Dr. Miriam Bornhorst)
Be Biopharma (Dr. Huei-Mei Chen)
Boston Children's Hospital (Dr. Catherine Brownstein)
Brigham and Women's Hospital (Dr. Phillip Michaels)
Drexel University (Dr. Ming Xiao)
Labcorp (Dr. Adam C. Smith)
Seattle Children's Hospital (Dr. Cate Paschal and Dr. Anica Wandler)
Stanford University (Dr. Alexander E. Urban)
Texas A&M University (Dr. Kenneth S. Ramos)
The Jackson Laboratory (Dr. Mark Adams, Dr. Charles Lee, Dr. Feyza Yilmaz)
The Translational and Advanced Medicine Center (Dr. Kevin P. Clancy)
University of Florida (Dr. Eric Wang)
Yale University (Dr. Ryan B. Jensen)
'Collaborations through the OhmX RAMP UP Grant Program represent our commitment to advancing genomic research by empowering the world's leading institutions with cutting-edge technology,' said Craig Kerkove, President & CEO, HTA. 'We are proud to support the groundbreaking work of these researchers, who are at the forefront of understanding and addressing the complexities of genetic diseases and cancer.'
'In awarding OhmX instruments to these prestigious laboratories, we have made a significant step forward in our mission to democratize access to genomic tools,' noted Nabsys CEO, Dr. Barrett Bready. 'This collaboration between Nabsys and HTA exemplifies our shared vision of powering innovation to drive transformative advancements in genomics and healthcare.'
OhmX's electronic nanochannel-based platform allows researchers to conduct targeted and whole-genome structural-variant analysis, leading to a better understanding of disease mechanisms, gene disruption, and complex genomic regions. This improved understanding empowers precision medicine with the potential to create more effective and personalized treatments, while also overcoming the cost and complexity barriers that are typically associated with SV analysis.
About Nabsys 2.0, LLC
The Nabsys 2.0, LLC ('Nabsys') mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis. For more information, visit https://www.nabsys.com.
About Hitachi High-Tech America, Inc.
Hitachi High-Tech America, Inc. (HTA) is a privately-owned global affiliate company that operates within the Hitachi Group companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products, as well as industrial equipment, and electronic and industrial materials. HTA is dedicated to successful and profitable collaboration with leading companies worldwide, with a direction towards providing customers with superior quality products and services at fair and competitive prices. For more information, please visit https://www.hitachi-hightech.com/us/en.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
29-07-2025
- CBS News
Boston Children's nurse completes virtual Pan-Mass Challenge after missing race for stem cell donation
A Boston Children's Hospital nurse wasn't expecting to be in a hospital bed when she was meant to be riding in the Pan-Mass Challenge, but she was grateful it was for a life-changing reason: stem cell donation. Kristin McIntire is no stranger to long rides. The Boston nurse has completed 10 marathons and several 100-mile bike races. "I love exercise. I love being active," she said, jokingly adding that she commutes to work on her bike. "I don't know if you're familiar with Boston traffic, but it's certainly the most easy way to get around." But for McIntire, riding has always been about more than just fitness. It's personal and it's purposeful. "I've always needed to align that with a higher purpose, that I don't feel like I'm doing it by myself. So whether that's riding with a team, running with a team fundraising for a group, it's been a lot more meaningful for me," McIntire said. For years, McIntire served as a pediatric oncology nurse at Boston Children's Hospital, working on one of the most intense and emotional floors in the building. "There are other outcomes that aren't so great... where the family is leaving without their child," she recalled. "And that's really, really sad." She rides in the Pan-Mass Challenge with Pedal for Pediatrics, a team made up of coworkers that raises money for children and families facing cancer at Dana-Farber and Boston Children's. But last year, just as she was preparing for the big ride, Kristin received a life-changing message: she'd been matched as a stem cell donor. "It was honestly so crazy. I was like, wait, what?" McIntire said. She spent what would've been Pan-Mass Challenge weekend in a hospital bed in Florida, donating stem cells to a stranger with leukemia. "That was a pretty cool reason to stop training, I would say," McIntire said. Though she couldn't be on the course, McIntire found another way to finish the journey. In the weeks after her donation, she completed multiple 50-mile rides virtually. "This team directly provides funding that benefits those patients directly, whether that's ride share services or meal coupons, anything that can help support this family," McIntire said. McIntire has never met the person she helped. She doesn't even know their name. But she knows they're still alive. "I saved a person's life, and I was a little tired after the donation, and that was it," McIntire said. "Whether you're riding, whether you're volunteering, or whether you're out there cheering— all of that matters, and it's very important work," she added. McIntire's stem cell procedure was not a traditional bone marrow surgery. Most donations today are done through a simple outpatient blood draw called peripheral blood stem cell donation. You can learn more or join the registry here.
Business Wire
14-07-2025
- Business Wire
Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today published a whitepaper titled ' Solving the Biosimilar Void in Europe ' that proposes policy recommendations to fully recognize the value of biosimilars and ensure a more sustainable market in Europe. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience. Share Biosimilars have played a significant role in alleviating the financial burden on the European healthcare system, having delivered €56 billion in cumulative cost savings across Europe over the past 11 years (2013-2024). 1 However, the current policy environment in Europe, particularly the post-launch pathways, is misaligned to incentivize biosimilar competition. With post-marketing challenges, on top of high development costs, many biologics will not face biosimilar competition at the point of loss of exclusivity (LoE) within the next decade. The whitepaper proposes several measures to improve current practices that hinder healthy market competition and timely access to biosimilar medicines: Health Technology Assessment (HTA) needs to be tailored for biosimilars: With its origin in innovative medicine, HTA is a multidisciplinary process that evaluates the medical, social, economic, and ethical implications of health technologies. Some countries often have oversimplified HTA requirements for biosimilars, where reimbursement decisions are solely based on price comparisons and do not take into account biosimilars' additional benefits or where the reference biologic is not reimbursed. In many cases, HTA is relevant, but with limited guidance to properly assess the biosimilar's value. HTA can be more streamlined and tailored to speed up the entry of biosimilars to the market. In some countries, pricing and reimbursement (P&R) policies focus on achieving the lowest possible prices through mechanisms such as price linkage and reference pricing, thereby accelerating price erosion: Out of 28 European countries, 12 countries use external reference pricing methods and 17 countries mandate arbitrary discounts on biosimilar prices at an average of 28% below reference product. 2 Already set at significantly lower levels, biosimilar prices are driven further downward as competition begins, often leading to price erosion that drives players out of the market. Instead of arbitrary price-controls, free pricing will allow price discounts to be achieved naturally through free competition. Tenders often favor a single-winner system and tend to overlook broader qualitative factors such as supply stability and quality assurance: National, regional, and local tenders should support supply diversification and fair competition through multi-winner systems, with greater transparency in communication and more periodic tender reopenings so that late entrants are also given opportunities to participate. Security and stability of supply should be given higher priority in tenders to enhance demand predictability and incentivize manufacturers to secure more robust supply chains. Biosimilar uptake cannot be achieved without the support of physicians and pharmacists who prescribe and dispense these medicines: Incentives extended to healthcare professionals to encourage the prescribing and dispensing of biosimilars vary significantly across European countries. In some countries, prescriber incentives are misaligned, discouraging the use of biosimilar medicines. Incentive programs should be based on shared decision-making between physicians and patients, rather than automatic switching. Gainsharing can be introduced to stimulate biosimilar uptake while preserving competition and autonomy. Education programs for physicians, pharmacists, and patients should be continued to support wider use of biosimilars. 'Biosimilars are not one-size-fits-all, and establishing a sustainable framework for biosimilars requires a nuanced understanding of their heterogeneous applications across clinical settings. It is vital to tailor key solutions that address the unique challenges faced by different product types, prescribing patterns, and patient and disease characteristics. It is also important to consider the future viability of the market when reshaping policies, as the market needs clear signals of long-term sustainability to encourage continued investments in the biosimilar pipeline,' said Adam Levysohn, Vice President and Head of Commercial Strategy Europe, at Samsung Bioepis. 'It is important for healthcare systems to recognize that biosimilars are not merely a cost-saving tool for organizations. Policies should take a patient-centric approach, positioning biosimilars as part of the solution to expand access, improve patient outcomes, ensure supply continuity, and strengthen system resilience.' Samsung Bioepis is a biopharmaceutical company that develops and manufactures high-quality biosimilars to accelerate patient access to biologic medicines. As a world leader in biosimilars, Samsung Bioepis has a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. Of the 11 biosimilars approved worldwide, eight products are available across Europe. To access the report Solving the Biosimilar Void in Europe, please visit HERE. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.
Boston Globe
09-07-2025
- Boston Globe
Nursing students could get debt relief from Boston startup Clasp
The company arranges loans for students studying to become nurses, physical therapists, optometrists, and other medical roles. Clasp matches each student borrower with an employer who agrees to hire the student after graduation. The employer also agrees to pay back a portion of the student's loans in return for a commitment of two to three years of work. The result is more workers for participating employers and a reduced debt burden for their workers, according to Clasp chief executive Tess Michaels. Advertisement The company announced on Wednesday that health care providers including Boston Children's Hospital, Memorial Sloan Kettering in New York, and multi-state network Novant Health would participate in the program. The idea for Clasp, which changed its name from Stride Funding last year, germinated while Michaels attended Harvard Business School. Pondering her own tuition costs and asking around, Michaels said she had an 'a-ha' moment. 'What if you could actually tie the cost of education to the outcomes [and] connect the education to the employment,' she said. Advertisement Michaels has raised $30 million of venture capital backing and struck a deal this year with financial lenders to loan $75 million to students. Unlike most other private student loan programs, Clasp's loans don't require a co-signer. Since the company was founded in 2018, more than 10,000 students have gotten loans through its platform, Michaels said. The company makes money from fees it charges participating institutions, but Clasp does not charge students or receive fees on loans. Some prior employment and loan repayment programs foundered because they included penalties if a worker decided to leave a job before their commitment was up, according to George Washington University professor Patricia Pittman, who studies health care workforce issues. Clasp's agreements don't have penalties or allow employers to claw back prior payments. Employers also can't reduce a promised salary or cut benefits. If a worker leaves before the end of their commitment, they face only the loss of future loan repayments. Claw-backs and other harsh repayment provisions are 'potentially exploitative' if workers are financially penalized for leaving early, Pittman said. 'Without the ability to quit, employers have fewer incentives to create healthy, ethical working conditions,' she said. 'The use of these contract breach fees is common with internationally recruited nurses and has led to many abuses as well as below-market wages.' Solving worker shortages will require more worker-friendly terms, Michaels said. 'In order to make a workforce sustainable, you've got to think about how you build trust and loyalty,' she said. North Carolina-based Novant Health started working with Clasp to recruit nurse anesthetists. The goal was to hire nurses for hard-to-fill positions and reduce turnover. 'The workforce of tomorrow depends on how we support students today,' Sebastien Girard, Novant's chief people officer, said in a statement. 'By relieving financial burden upfront, we're building loyalty from day one.' Advertisement The overall shortage of health care workers is getting worse as a growing aging population requires more care and workers from the Baby Boom generation retire. By 2035, the US system faces a shortage of more than 230,000 registered nurses and almost 270,000 licensed practical nurses, according to In Massachusetts, the Michaels wants Clasp to provide a model for the industry to become more creative and generous in recruiting the workers it needs. 'Part of my mission is to reimagine how we think about investing in talent,' she said. 'That just requires a shifting mindset of what is the art of the possible.' Aaron Pressman can be reached at
